Last reviewed · How we verify
BCG Vesiculture
BCG Vesiculture is a live attenuated Bacillus Calmette-Guérin vaccine formulation designed to stimulate innate and adaptive immune responses against bladder cancer.
BCG Vesiculture is a live attenuated Bacillus Calmette-Guérin vaccine formulation designed to stimulate innate and adaptive immune responses against bladder cancer. Used for Non-muscle invasive bladder cancer (NMIBC), high-grade urothelial carcinoma.
At a glance
| Generic name | BCG Vesiculture |
|---|---|
| Sponsor | Janssen Research & Development, LLC |
| Drug class | Live attenuated vaccine |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
BCG is administered intravesically (directly into the bladder) where it colonizes the urothelium and triggers a robust local immune response, including activation of dendritic cells, T cells, and natural killer cells. This immune activation leads to recognition and destruction of bladder cancer cells, particularly urothelial carcinoma. The vesiculture formulation refers to the specific culture and preparation method used by Janssen to optimize immunogenicity.
Approved indications
- Non-muscle invasive bladder cancer (NMIBC), high-grade urothelial carcinoma
Common side effects
- Dysuria
- Urinary frequency
- Hematuria
- Fever
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BCG Vesiculture CI brief — competitive landscape report
- BCG Vesiculture updates RSS · CI watch RSS
- Janssen Research & Development, LLC portfolio CI